SBC

SBC Medical Group Holdings Incorporated

$5.29

0.57%
SectorIndustrialsIndustryConsulting ServicesCountryUnited States

SBC Medical Group Holdings Incorporated, together with its subsidiaries, provides management services to cosmetic treatment centers in Japan, Vietnam, the United States, and Singapore. The company offers advertising and marketing services across social media networks; staff management services, such as recruitment and training; booking reservations for franchisee clinic customers; assistance with franchisee employee housing rentals; leasehold improvement services; and design services for clinics, medical equipment, and medical consumables procurement. It also provides loyalty program management, labor and function supporting, and management consulting services; and IT software solutions, as well as engages in franchising activities; and distributes medical equipment and devices, implants, injection materials, other medical consumables, skin care and beauty products, and cosmetic products to franchisee clinics for resale to clinic customers.

Source: Yahoo Finance
AI summary

Price & performance

1M+4.5%
3M+68.4%
YTD+22.9%
1Y+62.7%
52-week range—
Beta0.38
Full chart and returns against a benchmark

Q-Score

59/ 100

Quality against peers; 50 is the peer median.

Growth43
Risk42
Performance45
Valuation73
Profitability74
Leverage68
Sentiment61
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$173.6M-15.5%
Net income$51M+9.4%
Net margin29.4%+6.7 pts
Historical fundamentals

Red flags in filings

2active red flags
Material weakness in controlsMar 27, 2026
Exchange listing noticeJul 14, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer24%
Regions, segments, customers and suppliers

Valuation

SBCIndustryP/E11.1024.12P/S3.112.40EV/EBITDA5.7914.79P/B2.068.95PEG0.240.24
Dividend yield0.00%
Every valuation metric

Earnings

Nov 13next report, before the open
EPS estimate$0.12
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate